IFN-γ treatment, however, did not improve plasma ALT and AST levels (ALT levels: PF 15.3 ± 4.2 U/L vs. AF 70.0 ± 8.9 U/L, p < 0.01, AF vs. AF+IFN-γ 62.9 ± 8.4 U/L, p = 0.125; AST levels: PF 19.7 ± 4.0 U/L vs. AF 57.1 ± 8.3 U/L, p < 0.01, AF vs. AF+IFN-γ 63.2 ± 9.1 U/L, p = 0.538). The gene discussed is IFNG; the disease is atrial fibrillation.